Icahn and Singer Ru...
Health Care: Drugs
Synta Pharmaceuticals Inc. (SNTA: NASDAQ)
$7.50 0.01 | 0.13%
05/17/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -62.79M | -47.38M | -37.47M | 79.09M |
| Operating Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 0.00 | 116.00K | -116.00K | 16.00M |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 151.00K |
| (Decrease) Increase In Payables | 2.19M | 1.54M | -2.03M | 626.00K |
| (Decrease) Increase In Other Current Liabilities | 2.45M | 730.00K | 102.00K | -8.63M |
| (Increase) Decrease In Other Working Capital | 173.00K | -7.00M | -4.66M | -122.17M |
| Other Non-Cash Items | 3.32M | 3.35M | 4.05M | 4.58M |
| Net Cash From Continuing Operations | -54.14M | -47.30M | -38.20M | -26.81M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -54.14M | -47.30M | -38.20M | -26.81M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 40.60M | 60.74M | 17.25M | 60.81M |
| Purchases of Property, Plant & Equipment | -505.00K | -690.00K | -136.00K | -454.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | -50.03M | -50.73M | -36.92M | -39.30M |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -9.94M | 9.33M | -19.80M | 21.05M |
| Issuance of Debt | 0.00 | 2.00M | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 119.79M | 0.00 | 31.99M | 50.00K |
| Repayment of Long-Term Debt | -4.23M | -378.00K | -1.83M | -2.18M |
| Repurchase of Capital Stock | -32.00K | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | -12.00K | 35.11M | 15.00M | 0.00 |
| Net Cash From Financing Activities | 115.52M | 36.74M | 45.16M | -2.13M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 51.44M | -1.24M | -12.84M | -7.89M |
Portfolios with SNTA
- Portfolio NameUser Type
- ContributorEarnings Short Squeeze Play...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks With Big Insider Buy...
- UserPharma
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
- Userinsider buying
Latest SNTA Headlines from TheStreet
- Synta Is a Run-Up Trade Into ASCO Lung Cancer Data 05.14.13 | 10:05 am
- Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarin 05.10.13 | 07:05 am
- Synta Pharmaceuticals Becomes Oversold (SNTA) 05.08.13 | 04:05 pm
- Biotech Stock Mailbag: ASCO, Sarepta, Cel-Sci and Hate Mail! 04.26.13 | 08:04 am
- Insiders Trading GHDX ASCMA GNC SNTA 11.15.12 | 09:11 am
- The Next Big Thing in Biotech: Cancer Drugs
09.21.12 | 07:09 am - 5 Stocks Under $10 Set to Soar 09.20.12 | 01:09 pm
- 5 Stocks Under $10 Soaring Higher 09.13.12 | 02:09 pm
- 5 Stocks With Huge Insider Buying 07.11.12 | 10:07 am
- Insiders Trading SNTA, VMW, ENSG, AFG 07.03.12 | 10:07 am
Press Releases for SNTA
- Synta Provides Company Updates And Reports Fourth Quarter And Year-End 2012 Financial Results - Business Wire 03.14.13 | 07:03 am
- Synta Announces Appointment Of Sumant Ramachandra, M.D., Ph.D. As President, Research And Development - Business Wire 03.13.13 | 04:03 pm
- Synta To Host Conference Call And Webcast Of Fourth Quarter And Year-End 2012 Financial Results On March 14, 2013 - Business Wire 02.25.13 | 07:02 am
- Synta To Present At Upcoming Conferences - Business Wire 02.11.13 | 08:02 am
- Synta Pharmaceuticals Announces $60 Million Registered Direct Common Stock Offering - Business Wire 12.13.12 | 07:12 am
- Synta Pharmaceuticals Announces Proposed Registered Direct Offering Of Common Stock - Business Wire 12.12.12 | 04:12 pm
- Synta To Present At The Deutsche Bank 2012 DbAccess BioFEST - Business Wire 11.27.12 | 07:11 am
- Interim Results Of The Phase 2b/3 GALAXY Trial To Be Presented At The Fifth Asia Pacific Lung Cancer Conference - Business Wire 11.26.12 | 07:11 am
- Synta To Present At The Lazard Capital Markets 9th Annual Healthcare Conference - Business Wire 11.09.12 | 08:11 am
- Interim Results Of The Phase 2b GALAXY Trial To Be Presented At The Chemotherapy Foundation Symposium - Business Wire 11.07.12 | 08:11 am
Partner Headlines for SNTA
- BlackBerry Will Underperform and 4 More Analyst Notes to Looks At - Wall St. Cheat Sheet 04.01.13 | 04:04 am
- BlackBerry Will Underperform and 4 More Analyst Notes to Looks At - Wall St. Cheat Sheet 04.01.13 | 04:04 am
- Trius Therapeutics: New MSRA Treatment Could Bring Billions In Revenues - Seeking Alpha 03.05.13 | 09:03 am
- Insiders Love These 3 Highly Shorted Healthcare Stocks - Seeking Alpha 01.23.13 | 09:01 am
- UPDATE: Stifel Nicolaus Initiates Synta Pharmaceuticals at Hold; Enthusiasm Outpaces Expectations - Benzinga 08.30.12 | 01:08 pm
- Weekly CEO Buys Highlight: SNTA, MEI, PZG, MCHX, CMXI - GuruFocus 07.07.12 | 11:07 pm
- Vertex Pharmaceuticals CRASHES 16% with 3 NASDAQ Top Percentage Losers - Wall St. Cheat Sheet 06.29.12 | 10:06 am
- Healthcare Business Recap: Orexigen RIDES Arena, Anthera IMPLODES - Wall St. Cheat Sheet 06.28.12 | 08:06 am
- Analyst Says BUY Arena and 4 Equity Insights to Analyze Now - Wall St. Cheat Sheet 06.28.12 | 03:06 am
- New Lease Agreements for Alexandria - Analyst Blog - Zacks 06.08.12 | 05:06 pm
